Global orthobiologics market valued at $5.4 billion in 2021 is expected to witness a decent growth rate of 7% over the next 5 years

Global orthobiologics market valued at $5.4 billion in 2021 is expected to witness a decent growth rate of 7% over the next 5 years

Medi-Tech Insights: Increase in cases of sports injuries and road accidents, increase in the geriatric and obese population worldwide, growing number of people with arthritis and other spine-related disorders, preference increasing number of patients for minimally invasive procedures and mechanical advances in biomaterials. key factors driving the growth of the global orthobiologics market.


The description:

Orthobiologics uses biomaterials and cellular therapies to rapidly heal musculoskeletal injuries and support tissue healing and restoration through their regenerative potential. These products are derived from compounds found naturally in the body and interact dynamically with the musculoskeletal system to facilitate the healing of diseased or injured bones, cartilage, ligaments and menisci and tendons.

Technological Aprogress in Orthobiological Market at Fuel his World Market Dmother

Steady advancements in orthobiology have resulted in the development of effective products with advanced patient healing capabilities and increased applications, among others. Such advancements tend to provide a competitive edge to all the global manufacturers and hence all the major players continuously focus on investing in research activities for new product development and expansion of their reach. to strengthen their position in the orthobiologics market. Some of the technological advancements are listed below:

  • In June 2022, Organic products from Istos launched the Influx Fibrant line of 100% cortical allograft products featuring patented TheraCell technology and designed to advance patient healing.
  • In March 2022, sea ​​thorn launched new orthobiologic products – NorthStar Cervical Facet Fusion and Flash Navigation Lumbar Facet Fusion, with the goal of streamlining repeatable procedural workflow while maximizing fusion area.
  • In September 2020, Cerapedia has received Health Canada approval for its i-FACTOR+ Matrix bone graft. This next-generation bone graft is based on the osteogenic cell-binding peptide P15 which supports bone growth through cell attraction, attachment and activation.

Obtain Detailed insights on Orthobiologics market with sample PDF report @

Key S-growthtreaties Aadopted by Leading Mmarket Players operating in Orthobiologics market

Major market players working in the global orthobiologics market have embraced acquisition and partnership as a key growth strategy to expand their product offerings, enhance their geographic presence and distribution capabilities, and co-develop advanced products. Some of these developments are listed below-

  • In August 2022, Orthofix Medical Inc. has entered into a strategic partnership with CGBio, a developer of synthetic bone grafts, to co-develop and commercialize Novosis’s recombinant human bone morphogenetic protein 2 (rhBMP-2) bone growth materials and other tissue regeneration solutions for the Canadian and American markets.
  • In July 2021, Cellularity Inc. and Arthrex, Inc.. entered into a supply and distribution agreement for the distribution and commercialization of several products, including Celularity’s placenta-derived biomaterials products for orthopedics and sports medicine in the United States.
  • In March 2021, SeaSpine Holdings Corporation has entered into an agreement to acquire 7D Surgical, Inc., a Canadian medical device company. This acquisition was intended to combine the spinal implant and orthobiologics portfolios to advance spine surgery.

Irrespective of the market challenges such as unfavorable reimbursement scenario and pricing pressure on market players, the global orthobiologics market is growing fast and is expected to gain momentum in the coming years owing to a focus on the spinal fusion segment, demineralized bone sealants with excipients, the increasing use of viscosupplements, and whole-procedure innovations, among others.

For example, during the forecast period, the viscosupplements segment is expected to be driven by advances in hyaluronic acid therapies, rising prevalence of lifestyle-induced disorders, high efficacy in delaying procedures for total knee replacement and the growing preference for non-surgical treatments. for osteoarthritis. Moreover, conventional techniques such as autograft and allograft are difficult to manage, painful for the patient, have quite contrasting results and may require repeated surgeries. Therefore, an easier-to-use solution is likely to be accepted by physicians and healthcare providers which has a higher success rate from a medical and financial standpoint, providing opportunities for market players in this space.

Competitive landscape analysis: Orthobiologics market

The global orthobiologics market is marked by the presence of established market players such as Medtronic Plc (Ireland); Zimmer Biomet Holdings, Inc. (USA); Arthrex, Inc. (USA); Bioventus (United States); DePuy Synthes (Johnson & Johnson Services, Inc.) (USA); Stryker Corporation (USA); MTF Biologics (USA); and others.

Obtain a Custom Report on Orthobiologics market @

About Medi-Tech Knowledge:

Medi-Tech Insights is a business research and analytics company focused on healthcare. Our clients include Fortune 500 companies, blue chip investors and hyper-growth start-ups. We have successfully completed more than 100 projects in digital health, health informatics, medical technology, medical devices and pharmaceutical services.

Contact us:
Ruta Halde
Partner, Medi-Tech Insights
+32 498 86 80 79

#Global #orthobiologics #market #valued #billion #expected #witness #decent #growth #rate #years

Leave a Comment

Your email address will not be published. Required fields are marked *